HK1152494A1 - Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions - Google Patents

Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Info

Publication number
HK1152494A1
HK1152494A1 HK11106676.5A HK11106676A HK1152494A1 HK 1152494 A1 HK1152494 A1 HK 1152494A1 HK 11106676 A HK11106676 A HK 11106676A HK 1152494 A1 HK1152494 A1 HK 1152494A1
Authority
HK
Hong Kong
Prior art keywords
strontium
water
cartilage
treatment
salts
Prior art date
Application number
HK11106676.5A
Other languages
English (en)
Inventor
Stephan Christgau
Christian Hansen
Jens Andersen
Henrik Nilsson
Original Assignee
Osteologix As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33437111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1152494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osteologix As filed Critical Osteologix As
Publication of HK1152494A1 publication Critical patent/HK1152494A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/19—Pyruvic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
HK11106676.5A 2003-05-07 2011-06-29 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions HK1152494A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300691 2003-05-07
DKPA200300932 2003-06-20
US52844203P 2003-12-09 2003-12-09
DKPA200301820 2003-12-09

Publications (1)

Publication Number Publication Date
HK1152494A1 true HK1152494A1 (en) 2012-03-02

Family

ID=33437111

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106676.5A HK1152494A1 (en) 2003-05-07 2011-06-29 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Country Status (14)

Country Link
US (2) US7595342B2 (xx)
EP (3) EP2266585B1 (xx)
JP (3) JP4354984B2 (xx)
AT (1) ATE342722T1 (xx)
AU (1) AU2004237439B2 (xx)
CA (1) CA2519189C (xx)
CY (1) CY1105935T1 (xx)
DE (1) DE602004002832T2 (xx)
DK (1) DK1534305T3 (xx)
ES (1) ES2275218T3 (xx)
HK (1) HK1152494A1 (xx)
PL (3) PL2266585T3 (xx)
PT (1) PT1534305E (xx)
WO (1) WO2004098619A2 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004237437B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Controlled release composition containing a strontium salt
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
KR101165614B1 (ko) 2004-02-26 2012-07-18 오스테올로지스 에이에스 괴사성 골 질환의 예방 또는 치료에 사용하기 위한스트론튬 함유 화합물
CA2565840A1 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
CA2570389A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
MXPA06015187A (es) 2004-06-25 2007-09-27 Strontin Aps Composiciones que comprenden estroncio y vitamina d y usos de las mismas.
EP2801354B1 (en) 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PL372183A1 (pl) * 2005-01-11 2006-07-24 Sgp & Sons Ab Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
DE102005012971A1 (de) * 2005-03-21 2006-09-28 Merckle Gmbh Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure
EP1899314A2 (en) * 2005-07-06 2008-03-19 Osteologix A/S High yield synthesis methods for producing organic salts of strontium
US8624041B2 (en) 2005-08-19 2014-01-07 Glenmark Generics Ltd. Process for the preparation of strontium ranelate
US20090312427A1 (en) * 2005-11-15 2009-12-17 Entress Ab Medicament for Use in Connection With Cartilage Impairment
EP2029184B1 (en) 2006-05-26 2011-02-23 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101668549B (zh) * 2007-04-23 2014-04-09 巴克斯特国际公司 包含锶化合物的纤维蛋白组合物
US8372992B2 (en) * 2007-06-01 2013-02-12 Nutraceutical Corporation Strontium (M) ascorbate, compositions containing same, method for making same and method of using same
EP2014319A1 (en) 2007-07-09 2009-01-14 Astra Tech AB A bone tissue implant comprising strontium ions
EP2014259A1 (en) 2007-07-09 2009-01-14 Astra Tech AB A bone tissue implant comprising lithium ions
US8378126B2 (en) * 2007-08-01 2013-02-19 Nutraceutical Corporation Strontium (M) ascorbate, compositions containing same, method for making same and method of using same
KR101699912B1 (ko) 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
WO2010117346A2 (en) 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
BR112013006331B1 (pt) 2010-09-16 2021-09-21 Shimoda Biotech (Pty) Ltd Formulação compreendendo fulvestranto e ciclodextrina e seu uso
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
US9301945B2 (en) * 2011-07-21 2016-04-05 Emory University Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
US10232090B2 (en) 2013-08-23 2019-03-19 Southwest Research Institute Electrophoretically deposited strontium fluoride nanoparticle/polymer coatings for medical implants
US9820968B2 (en) * 2013-09-24 2017-11-21 Council Of Scientific And Industrial Research Anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells
RU2547787C1 (ru) * 2013-12-16 2015-04-10 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт травматологии и ортопедии имени В.Д. Чаклина" Министерства здравоохранения Российской Федерации Способ оптимизации состояния суставного хряща при экспериментальном иммобилизационном остеопорозе
CN106163513A (zh) * 2014-02-12 2016-11-23 加利福尼亚大学董事会 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
WO2016130686A1 (en) 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Stable high concentration strontium compounds and formulations for topical application
WO2016141219A1 (en) 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
CA2958169A1 (en) 2016-08-17 2018-02-17 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US10463636B2 (en) 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
US20210161950A1 (en) * 2017-12-15 2021-06-03 Lewis Kilman Clarke Veterinary Supplement for Effecting Bone and Cartilage
US11530232B2 (en) * 2019-11-14 2022-12-20 Alliance For Sustainable Energy, Llc Reversibly soluble bases for lignin oxidative depolymerization
RU2730133C1 (ru) * 2020-05-04 2020-08-18 Евгений Владимирович Плотников Геропротекторное средство
CN114716310A (zh) * 2022-06-08 2022-07-08 中国科学院过程工程研究所 一种柠檬酸锶及其制备方法

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB241266A (en) 1924-07-14 1925-10-14 Knoll & Co Chem Fab Improvements in the manufacture of double compounds of dimethylxanthines, earth alkali and salicylic acid
BE532864A (xx) 1952-04-29
GB990957A (en) 1964-02-24 1965-05-05 Stafford Miller Ltd Strontium ion-containing toothpaste
SE340807B (xx) * 1966-05-06 1971-12-06 Astra Ab
US4056567A (en) * 1976-03-08 1977-11-01 Lever Brothers Company Chemical processes for preparing citric acid
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
DE3735264C1 (de) * 1987-10-17 1988-08-25 Degussa Verfahren zur Herstellung von Erdalkalimetallsalzen der L-2-Pyrrolidon-5-carbonsaeure
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
FR2633619B1 (fr) 1988-06-29 1991-02-08 Adir Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0381445B2 (en) 1989-01-31 1998-01-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental composition for hypersensitive teeth
GB8906914D0 (en) 1989-03-28 1989-05-10 Beecham Group Plc Novel compositions
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2658816A1 (fr) 1990-02-27 1991-08-30 Adir Nouveaux sels de metaux alcalinoterreux d'oxa-polyacides leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2665896A1 (fr) 1990-08-16 1992-02-21 Rhone Poulenc Chimie Carboxylates metalliques, leur preparation et compositions supraconductrices obtenues a partir de ceux-ci.
WO1994015932A1 (en) 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
CN1061036C (zh) 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5475021A (en) * 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
AU692231B2 (en) 1994-02-10 1998-06-04 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0809636B1 (en) 1995-02-13 2002-09-04 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
JPH11501049A (ja) 1995-04-04 1999-01-26 グラクソ、グループ、リミテッド イミダゾ〔１，２−ａ〕ピリジン誘導体
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
WO1996036617A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
PT848703E (pt) 1995-07-21 2001-01-31 Nycomed Austria Gmbh Derivados de benzosulfonamidas como inibidores da enzima ciclo-oxigenase ii
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5906809A (en) * 1995-10-19 1999-05-25 University Of Maryland, Baltimore One-step method and preparation for reducing dentinal hypersensitivity
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
US5977103A (en) 1996-01-11 1999-11-02 Smithkline Beecham Corporation Substituted imidazole compounds
NZ327022A (en) 1996-01-26 1999-06-29 Searle & Co Heterocyclo-substituted imidazoles for the treatment of inflammation
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
DK0888127T3 (da) 1996-02-13 2002-04-08 Searle & Co Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
ES2125161B1 (es) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S Nuevos derivados de 2-(3h)-oxazolona.
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
FR2747123B1 (fr) 1996-04-04 1998-06-26 Union Pharma Scient Appl Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
ES2311571T3 (es) 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US5756531A (en) * 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5696431A (en) * 1996-05-03 1997-12-09 Philips Electronics North America Corporation Inverter driving scheme for capacitive mode protection
WO1997044028A1 (en) 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044027A1 (en) 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
HRP970289A2 (en) 1996-05-31 1998-04-30 Merck & Co Inc Process for preparing phenyl heterocycles useful as cox-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5750558A (en) * 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
US5945538A (en) * 1996-06-28 1999-08-31 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2260016C (en) 1996-07-18 2004-03-09 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP2000515887A (ja) 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション Ｃｏｘ―２のピラノインドール系およびカルバゾール系阻害薬
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
ES2188971T3 (es) 1996-08-14 2003-07-01 Searle & Co Forma cristalina de la 4-(5-metil-3-fenilisoxazol-4-il)benzensulfonamida.
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
HUP9904696A2 (hu) 1996-11-12 2000-05-28 American Home Products Corporation COX-2 Enzim indén-típusú inhibitorai
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
DE69725171T2 (de) * 1996-12-10 2004-07-15 G.D. Searle & Co., Chicago Substituierte pyrrolylverbindungen zur behandlung von entzündungen
IT1298159B1 (it) 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US5792446A (en) 1997-02-18 1998-08-11 Collagenex Pharmaceuticals, Inc. Delivery system for administering dentin-hypersensitivity-ameliorating compositions
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
ATE244232T1 (de) 1997-03-14 2003-07-15 Merck Frosst Canada Inc (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
AU738727B2 (en) 1997-03-14 2001-09-27 Merck Frosst Canada Ltd. Pyridazinones as inhibitors of cyclooxygenase-2
AU6518598A (en) 1997-03-28 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6
CA2285567A1 (en) 1997-04-02 1998-10-08 Merck Frosst Canada & Co. Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
WO1998046594A1 (fr) 1997-04-11 1998-10-22 Grelan Pharmaceutical Co., Ltd. Derives de pyrazole et inhibiteurs de cox les renfermant
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
KR20010006443A (ko) 1997-04-18 2001-01-26 쥐.디. 씨얼리 앤드 컴퍼니 심장혈관 질환 예방에의 시클로 옥시게나제-2 억제제 사용방법
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
WO1998050075A1 (en) 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
EP0983260A2 (en) 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
ES2260846T3 (es) 1997-08-22 2006-11-01 Abbott Laboratories Inhibidores para la biosintesis de la prostaglandina h2 sintasa.
WO1999010331A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
YU11900A (sh) 1997-09-05 2002-11-15 Glaxo Group Limited Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2)
ES2239402T3 (es) 1997-09-12 2005-09-16 MERCK FROSST CANADA & CO. 2-aminopiridinas como inhibidores de ciclooxigenasa-2.
ES2226167T3 (es) 1997-09-12 2005-03-16 MERCK FROSST CANADA & CO. Piridinas 2,3,5-sustituidas como inhibidores de ciclooxigenasa 2.
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPO990097A0 (en) 1997-10-21 1997-11-13 University Of Sydney, The Medicinal uses of phenylalkanols and derivatives (gingerol analogues)
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2770131A1 (fr) 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
WO1999023087A1 (en) 1997-10-30 1999-05-14 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
BR9813164A (pt) 1997-10-31 2000-08-22 Searle & Co Método de uso de inibidores da ciclooxigenase-2 na manutenção do ducto arterial fetal durante o tratamento e prevenção de dores prematuras de parto
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU1691399A (en) 1997-12-26 1999-07-19 Nissin Food Products Co., Ltd. 5-arylpyrrole derivatives
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
WO1999034772A1 (en) 1998-01-09 1999-07-15 Enamelon, Inc. Solid products and methods for the remineralization and prevention of demineralization of teeth
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
AU754064B2 (en) 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
GB9810920D0 (en) 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
WO1999061016A1 (en) 1998-05-27 1999-12-02 Nippon Shinyaku Co., Ltd. Cyclooxygenase-2 inhibitors
ES2137138B1 (es) 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
TNSN99111A1 (fr) 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
SE9802333D0 (sv) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
JP2000016935A (ja) 1998-07-01 2000-01-18 Dai Ichi Seiyaku Co Ltd シクロオキシゲナーゼ阻害剤
GB9814316D0 (en) 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
ES2140354B1 (es) 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
DE19837522A1 (de) * 1998-08-19 2000-02-24 Clariant Gmbh Verwendung von Metall-Carboxylaten und -Sulfonaten als Ladungssteuermittel
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
BR9914858A (pt) 1998-10-27 2002-02-05 Abbott Lab Inibidores de biosìntese sintase h de endoperóxido de prostaglandina
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
CA2349567A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
AU1398899A (en) 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
WO2000029023A1 (en) 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
US6232497B1 (en) * 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
EP1140182A2 (en) 1998-12-23 2001-10-10 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
IL144126A0 (en) 1999-01-07 2002-05-23 Univ Vanderbilt A method of altering the specificity of cyclooxygenase-inhibiting compounds
AU3596500A (en) 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
US6498166B1 (en) 1999-02-27 2002-12-24 Smithkline Beecham Corporation Pyrazolopyridines
CN1349423A (zh) 1999-03-01 2002-05-15 奥索-麦克尼尔药品公司 包含曲马多物质和选择性cox－2抑制剂药物的组合物
ES2249253T3 (es) 1999-03-10 2006-04-01 G.D. Searle Llc Metodo y composicion para administrar un inhibidor de la ciclooxigenasa-2.
US6211210B1 (en) 1999-05-07 2001-04-03 Merck Frosst Canada & Co. Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US20020018748A1 (en) * 2000-04-03 2002-02-14 Stanley Satz Method for targeted radiotherapy, pain palliation and imaging of osteoblastic skeletal tumors and composition therefore
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
ATE496624T1 (de) 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
US6365152B1 (en) * 2001-03-15 2002-04-02 Bovine Health Products, Inc. Scours treatment and method of making same
WO2003003664A1 (en) 2001-06-27 2003-01-09 Hyglo Ab System and method for address and key distribution in virtual networks
NO20014746D0 (no) 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
SE0201713D0 (sv) 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
AU2003213682C1 (en) 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
US7273523B2 (en) 2002-06-07 2007-09-25 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
DE10225420A1 (de) 2002-06-07 2003-12-24 Sanatis Gmbh Strontium-Apatit-Zement-Zubereitungen, die daraus gebildeten Zemente und die Verwendung davon
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
EP1408375B1 (en) * 2002-10-10 2011-12-14 Canon Kabushiki Kaisha Yellow toner
FR2846558B1 (fr) 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
WO2004084920A2 (en) 2003-03-27 2004-10-07 Santosolve As Anti-inflammatory treatment based on strontium compounds
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
AU2004237437B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Controlled release composition containing a strontium salt
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
FR2862224A1 (fr) 2003-11-14 2005-05-20 Medesis Pharma Sa Complexes a base de strontium, pharmaceutiques et produits dietetiques
KR101165614B1 (ko) 2004-02-26 2012-07-18 오스테올로지스 에이에스 괴사성 골 질환의 예방 또는 치료에 사용하기 위한스트론튬 함유 화합물
CA2565840A1 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
WO2006089546A1 (en) 2005-02-28 2006-08-31 Osteologix A/S Tablets comprising a high load of strontium
WO2005123098A2 (en) 2004-06-17 2005-12-29 Osteologix A/S Preventing gastrointestinal side-effects with strontium salts
CA2570503A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S A method of improving the medical treatment of pain
CA2570389A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
EP1899314A2 (en) 2005-07-06 2008-03-19 Osteologix A/S High yield synthesis methods for producing organic salts of strontium

Also Published As

Publication number Publication date
PL1745791T3 (pl) 2013-11-29
US20060122274A1 (en) 2006-06-08
CA2519189A1 (en) 2004-11-18
EP1534305B1 (en) 2006-10-18
US8541471B2 (en) 2013-09-24
US20100048697A1 (en) 2010-02-25
EP1534305B9 (en) 2007-03-07
AU2004237439A1 (en) 2004-11-18
JP2006525243A (ja) 2006-11-09
DE602004002832D1 (de) 2006-11-30
EP2266585B1 (en) 2013-06-26
EP1745791A3 (en) 2011-03-30
CY1105935T1 (el) 2011-04-06
DK1534305T3 (da) 2007-02-05
CA2519189C (en) 2012-07-17
EP2266585A2 (en) 2010-12-29
JP2009263381A (ja) 2009-11-12
AU2004237439B2 (en) 2009-09-10
EP1745791B1 (en) 2013-06-26
ATE342722T1 (de) 2006-11-15
JP2012167100A (ja) 2012-09-06
PL1534305T3 (pl) 2007-03-30
US7595342B2 (en) 2009-09-29
JP5036765B2 (ja) 2012-09-26
EP2266585A3 (en) 2011-05-04
PL2266585T3 (pl) 2013-10-31
JP5244995B2 (ja) 2013-07-24
DE602004002832T2 (de) 2007-06-06
EP1745791A2 (en) 2007-01-24
WO2004098619A2 (en) 2004-11-18
EP1534305A2 (en) 2005-06-01
PT1534305E (pt) 2007-02-28
ES2275218T3 (es) 2007-06-01
WO2004098619A3 (en) 2005-03-10
JP4354984B2 (ja) 2009-10-28

Similar Documents

Publication Publication Date Title
HK1152494A1 (en) Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
TNSN05278A1 (en) Inhibitors of phosphatidylinositol 3-kinase
EP2308833A3 (en) Cyclic protein tyrosine kinase inhibitors
ATE457981T1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
UA81568C2 (en) Benzoyl-substituted phenylalanine amides, methods and intermediate products for the production thereof, herbicidal composition and method for controlling undesired plants
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MY135050A (en) Organic compounds
HK1075259A1 (en) Prodrugs of excitatory amino acids
RU2002133059A (ru) Полиамидный порошок для применения в составе косметических средств
ATE106404T1 (de) Angiotensin-ii-antagonisten.
MY152921A (en) Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives
ZA200508862B (en) Process for the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives thereof
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
MXPA02010822A (es) Metodo para incrementar la productividad de una planta usando acido glutamico y acido glicolico.
DE602004023102D1 (de) Verfahren zur herstellung kristalliner formen von orlistat
CY1114355T1 (el) Υδατοδιαλυτα αλατα στροντιου για χρηση στην θεραπεια των παθησεων του χονδρου ή/και των οστων
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE50213257D1 (de) Gabusectin-derivate, verfahren zur deren herstellung und deren verwendung
DE69110807T2 (de) Verfahren zur herstellung von equimolaren salzen von asparaginsäure und magnesium, magnesiumaspartatsalz nach diesem verfahren und ihre verwendung.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170506